(PDF) KRAS and Combined KRAS/TP53 Mutations in Locally

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer Are Independently Associated With Decreased Response to Neoadjuvant Therapy

Annals of Surgical Oncology - United States

doi 10.1245/s10434-016-5205-4

Full Text

Abstract

Available in full text

Categories

Date

March 28, 2016

Authors

J. Joshua Smith

Niedzica Camacho

Raphael Pelossof

Martin R. Weiser

Michael F. Berger

Emily Bergsland

Julio Garcia-Aguilar

Publisher

Springer Science and Business Media LLC

Related search

KRAS Mutations and Rectal Cancer Response to Chemoradiation: Are We Closer to Personalization of Therapy?

Annals of Surgical Oncology

English

MicroRNA Expression Profile Associated With Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients

Radiation Oncology

Nuclear Medicine

English

MRI-Based Radiomics Predicts Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Frontiers in Oncology

Cancer Research

English

Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer

Clinical Oncology

Nuclear Medicine

English

Recent Advances in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Journal of the Anus, Rectum and Colon

English

KRAS Genotyping in Rectal Adenocarcinoma Specimens With Low Tumor Cellularity After Neoadjuvant Treatment

Modern Pathology

Forensic Medicine

English

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Multidisciplinary

English

Phase 1b/2 Study of Neoadjuvant Chemoradiation Therapy With CRLX101 and Capecitabine for Locally Advanced Rectal Cancer

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

KRAS Mutations in Slovene Patients With Colorectal Cancer: Frequency, Distribution and Correlation With the Response to Treatment

International Journal of Oncology

Cancer Research

English